IDH1 and acute myeloid leukemia: Furthermore, this concept is currently reinforced by recent findings in older patients with newly diagnosed NPM1-mutated [16], IDH1-mutated [17], and IDH2-mutated [11] AML responding well to a combination of venetoclax and azacitidine as well as single-agent ivosidenib or enasidenib, respectively, and receiving an undetermined duration of consolidation/maintenance therapy.